Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
immunotherapy
sarcoma
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
accepted:
15
11
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
16
12
2021
Statut:
ppublish
Résumé
Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I-II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas.
Identifiants
pubmed: 33526607
pii: jitc-2020-001580
doi: 10.1136/jitc-2020-001580
pmc: PMC7852926
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: J-SD is an inventor on patents licensed to Turnstone Biologics, which is commercializing oncolytic Maraba virus. J-SD has patents licensed and also holds equity in Virica Biotech, which is developing oncolytic virus platforms.
Références
Mol Ther. 2018 Jan 3;26(1):56-69
pubmed: 29175158
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Commun. 2017 Mar 27;8:14754
pubmed: 28345650
Cancer Res. 2019 Jun 15;79(12):3112-3124
pubmed: 31015228
Cancer Invest. 2018;36(8):431-457
pubmed: 30325244
Oncoimmunology. 2020 Apr 12;9(1):1747340
pubmed: 32313727
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938
pubmed: 30231352
Br J Cancer. 2019 Jan;120(1):6-15
pubmed: 30413827
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Cancer. 2017 May 1;123(9):1576-1584
pubmed: 28241093
JAMA Oncol. 2017 Aug 01;3(8):1094-1101
pubmed: 28426845
Oncotarget. 2017 Aug 2;8(39):66137-66153
pubmed: 29029499
JAMA Oncol. 2018 Dec 1;4(12):1729-1735
pubmed: 30326045
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Clin Cancer Res. 2017 Jul 15;23(14):3566-3574
pubmed: 28495911
Pediatr Blood Cancer. 2016 Oct;63(10):1780-5
pubmed: 27304202
Methods Mol Biol. 2016;1441:285-95
pubmed: 27177675
Biologics. 2018 Dec 21;13:1-12
pubmed: 30613134
Viruses. 2017 Oct 17;9(10):
pubmed: 29039746
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Lancet Oncol. 2019 Jun;20(6):837-848
pubmed: 31078463
Cancer Sci. 2012 Sep;103(9):1625-30
pubmed: 22726592
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
J Virol. 2011 Sep;85(18):9346-58
pubmed: 21734048
Pediatr Blood Cancer. 2019 Oct;66(10):e27783
pubmed: 31304677
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Sci Rep. 2019 Oct 17;9(1):14916
pubmed: 31624330
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
ACS Infect Dis. 2018 Oct 12;4(10):1448-1467
pubmed: 30152676
Cell Death Dis. 2019 Jan 15;10(2):36
pubmed: 30674867
Viruses. 2018 Jun 03;10(6):
pubmed: 29865280
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
Int J Cancer. 2020 Jun 1;146(11):3184-3195
pubmed: 31621900
Am J Cancer Res. 2020 Feb 01;10(2):674-687
pubmed: 32195035
JAMA Oncol. 2020 Mar 1;6(3):402-408
pubmed: 31971541
Mod Pathol. 2019 Dec;32(12):1772-1785
pubmed: 31263176
Cancer Immunol Res. 2016 Oct;4(10):869-880
pubmed: 27549124
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
BMC Cancer. 2018 Sep 24;18(1):913
pubmed: 30249211
Oncol Lett. 2019 Apr;17(4):3937-3943
pubmed: 30881511
Oncoimmunology. 2018 Feb 15;7(5):e1423167
pubmed: 29721373
Front Oncol. 2018 Oct 17;8:435
pubmed: 30386736
Clin Sarcoma Res. 2017 Jul 14;7:14
pubmed: 28725344
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5):
pubmed: 31645345
Curr Cancer Drug Targets. 2010 Mar;10(2):200-9
pubmed: 20201786
Pharmacol Ther. 2015 Mar;147:22-31
pubmed: 25444759
J Bone Miner Res. 2018 Nov;33(11):2048-2058
pubmed: 29949655
Clin Cancer Res. 2017 Jul 15;23(14):3499-3509
pubmed: 28183713
Oncoimmunology. 2017 Oct 31;7(2):e1385689
pubmed: 29308306
J Hematol Oncol. 2020 Jul 2;13(1):86
pubmed: 32616000
Oncotarget. 2017 Jul 7;8(41):71371-71384
pubmed: 29050367
J Virol. 2014 May;88(9):4932-42
pubmed: 24554651
Cancer Lett. 2018 Mar 1;416:1-10
pubmed: 29104145
Pediatr Hematol Oncol. 2017 May;34(4):238-253
pubmed: 29065267
Sci Transl Med. 2018 Jan 24;10(425):
pubmed: 29367345
J Clin Med. 2016 Nov 03;5(11):
pubmed: 27827889
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Mol Pharm. 2019 May 6;16(5):2249-2258
pubmed: 30969779
J Immunother Cancer. 2017 Dec 19;5(1):98
pubmed: 29254507
Cancer Sci. 2019 Oct;110(10):3038-3048
pubmed: 31385405
J Glob Oncol. 2018 Sep;4:1-6
pubmed: 30241159
Front Oncol. 2019 Nov 14;9:1169
pubmed: 31799177
Cancer. 2020 May 1;126 Suppl 9:2093-2100
pubmed: 32293729
Clin Cancer Res. 2020 Mar 15;26(6):1258-1266
pubmed: 31900276
Clin Cancer Res. 2019 Apr 1;25(7):2096-2108
pubmed: 30573690
Virchows Arch. 2017 Sep;471(3):383-392
pubmed: 28744588
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
Am Fam Physician. 2018 Aug 15;98(4):205-213
pubmed: 30215968
Am J Clin Dermatol. 2017 Aug;18(4):529-539
pubmed: 28324233
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):395-402
pubmed: 17656146
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
Vaccine. 2018 May 17;36(21):3054-3060
pubmed: 29655625
Nat Commun. 2019 May 22;10(1):2272
pubmed: 31118418
Future Oncol. 2010 May;6(5):717-32
pubmed: 20465387
Front Immunol. 2019 Aug 02;10:1814
pubmed: 31428099
Cancer Res. 2019 Aug 1;79(15):3797-3805
pubmed: 31300476
J Clin Invest. 2018 Nov 1;128(11):5184
pubmed: 30277478
Open Access Maced J Med Sci. 2018 Sep 04;6(9):1555-1560
pubmed: 30337965
Memo. 2014;7(2):92-96
pubmed: 25089160
Cell Adh Migr. 2017 Jul 4;11(4):338-346
pubmed: 27532429
N Engl J Med. 1985 Jan 3;312(1):26-33
pubmed: 2856889
Clin Cancer Res. 2014 Oct 1;20(19):5097-112
pubmed: 25107916
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123